Trials / Unknown
UnknownNCT05724342
Tenecteplase REperfusion in Acute Ischemic sTroke Registry（TREAT）
Tenecteplase REperfusion in Acute Ischemic sTroke Registry
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,600 (estimated)
- Sponsor
- Beijing Tiantan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study was to establish tenecteplase thrombolysis database and to investigate the effectiveness and safety of rhTNK-tPA in acute ischemic stroke patients.
Detailed description
Tenecteplase (TNK), as a newer fibrinolytic agent, has practical delivery advantages over alteplase that would make it a potential alternative. Several randomized controlled clinical trials demonstrated the noninferiority of TNK but the evidence on the effectiveness and safety of TNK in the real-world is insufficient. This is a multi-center, prospective, registry cohort study that enrolled acute ischemic stroke patients treated with TNK thrombolysis in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhTNK-tPA Thrombolysis | rhTNK-tPA Thrombolysis |
Timeline
- Start date
- 2023-02-15
- Primary completion
- 2024-09-30
- Completion
- 2024-12-31
- First posted
- 2023-02-13
- Last updated
- 2023-02-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05724342. Inclusion in this directory is not an endorsement.